Please provide your email address to receive an email when new articles are posted on . Among patients with cardiogenic shock, there was no difference between the inotropic agents milrinone and ...
A head-to-head randomized comparison of milrinone and dobutamine — the most used inotropes in cardiogenic shock therapy in North America — failed to find a significant advantage for one agent over the ...
A head-to-head comparison of inotropes in the setting of cardiogenic shock revealed no clear victor, with milrinone and dobutamine providing similar outcomes in the randomized DOREMI trial. A ...
Against expectations, critically ill people in cardiogenic shock fared similarly receiving one widely used inotrope or another in the small DOREMI trial. Patients had the same clinical outcomes on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results